Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Kim-McOlash
Observed name:
Sarah Kim
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
University of Minnesota,
Fairview Health Services,
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
University of Minnesota System
ORCID:
0000-0002-6781-619X
Observed ORCID:
0000-0002-6781-619X
OpenAlex ID:
A5014397990
Infantile gangliosidoses: Mapping a timeline of clinical changes
2017
·
Jeanine R. Jarnes Utz
, Sarah Kim
, et al.
·
Molecular Genetics and Metabolism
·
92
PDF
A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I
2020
·
Li Ou
, Michael J. Przybilla
, et al.
·
Molecular Therapy
·
57
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
36
Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs
2019
·
Robert N. Schuck
, Michael Pacanowski
, et al.
·
Clinical and Translational Science
·
25
PDF
The juvenile gangliosidoses: A timeline of clinical change
2020
·
Kelly E. King
, Sarah Kim
, et al.
·
Molecular Genetics and Metabolism Reports
·
22
PDF
Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling
2019
·
Li Ou
, Sarah Kim
, et al.
·
Molecular Genetics and Metabolism Reports
·
20
PDF
Chitotriosidase as a biomarker for gangliosidoses
2021
·
Sarah Kim
, Chester B. Whitley
, et al.
·
Molecular Genetics and Metabolism Reports
·
11
Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report
2017
·
Sarah Kim
, Chester B. Whitley
, et al.
·
Molecular Genetics and Metabolism
·
9
PDF
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
·
Clinical Cancer Research
·
5
Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system
2022
·
Sarah Kim
, Michael J. Przybilla
, et al.
·
Molecular Genetics and Metabolism Reports
·
3
PDF
Supplementary Table S1 from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
·
1
Supplementary Table S1 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
PDF
Data from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
Supplementary Table S3 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
PDF
Data from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
Show more works
View as search
Works count:
16
Citation count:
281
H-index:
8
I10-index:
7
Year
Topic
Type